Peptide tag
Fat loss
Peptides that support metabolic function, appetite regulation, and healthy body composition.
The peptide landscape for fat loss and appetite management has expanded significantly with the development of GLP-1 receptor agonists and metabolic peptides. These compounds work through various mechanisms including appetite suppression, increased metabolic rate, improved insulin sensitivity, and targeted fat oxidation.
Unlike traditional weight loss approaches that rely solely on caloric restriction, peptide-based strategies can address the hormonal and neurological drivers of obesity. GLP-1 agonists like Semaglutide have shown unprecedented efficacy in clinical trials, while growth hormone fragments like AOD-9604 target fat metabolism specifically without the broader effects of full growth hormone therapy.
Research in this area is rapidly evolving, with multi-receptor agonists like Tirzepatide and Retatrutide showing even greater efficacy by targeting multiple metabolic pathways simultaneously.
Top picks
Top peptides for Fat loss
BPC-157
Body Protection Compound known for gut healing, tendon repair, and anti-inflammatory properties.
- Reduces appetite and food intake
- Improves blood sugar control
- Promotes significant weight loss
Full list
All peptides for Fat loss
Copper peptide promoting collagen synthesis, skin remodeling, and wound healing.
GHRP-2
Copper peptide promoting collagen synthesis, skin remodeling, and wound healing.
Body Protection Compound known for gut healing, tendon repair, and anti-inflammatory properties.
Copper peptide promoting collagen synthesis, skin remodeling, and wound healing.
Research
Science corner
Research shows AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, offering a targeted approach to fat loss.
View studyEmerging data on triple agonists (GLP-1/GIP/Glucagon) suggest up to 24% body weight reduction, representing a new frontier in metabolic peptide therapy.
View studyParticipants achieved mean weight loss of 14.9% over 68 weeks compared to 2.4% with placebo. The study demonstrated sustained appetite reduction and improved cardiometabolic markers.
View study